GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (BUE:LLY) » Definitions » Short-Term Debt

Eli Lilly and Co (BUE:LLY) Short-Term Debt : ARS1,971,622 Mil (As of Sep. 2024)


View and export this data going back to . Start your Free Trial

What is Eli Lilly and Co Short-Term Debt?

Eli Lilly and Co's Short-Term Debt for the quarter that ended in Sep. 2024 was ARS1,971,622 Mil.

Eli Lilly and Co's quarterly Short-Term Debt increased from Mar. 2024 (ARS1,391,389 Mil) to Jun. 2024 (ARS4,622,213 Mil) but then declined from Jun. 2024 (ARS4,622,213 Mil) to Sep. 2024 (ARS1,971,622 Mil).

Eli Lilly and Co's annual Short-Term Debt increased from Dec. 2021 (ARS155,353 Mil) to Dec. 2022 (ARS251,659 Mil) and increased from Dec. 2022 (ARS251,659 Mil) to Dec. 2023 (ARS2,492,525 Mil).

Eli Lilly and Co Short-Term Debt Historical Data

The historical data trend for Eli Lilly and Co's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Short-Term Debt Chart

Eli Lilly and Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 89,618.56 708.01 155,352.91 251,659.41 2,492,524.50

Eli Lilly and Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 785,532.79 2,492,524.50 1,391,388.77 4,622,212.73 1,971,622.06

Eli Lilly and Co Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Eli Lilly and Co Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Eli Lilly and Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (BUE:LLY) » Definitions » Short-Term Debt
Comparable Companies
JNJ ABBV MRK AMGN PFE BMY GILD BIIB OGN AMRN OCSE:NOVO B XSWX:ROG XSWX:NOVN LSE:AZN XPAR:SAN LSE:GSK TSE:4519 TSE:4568 SHSE:600276 TSE:4578
Traded in Other Exchanges
LLY:USA LLY:Mexico 1LLY:Italy LLY0:Germany LLY:Germany LLY:Germany LLY:Germany LLY:Germany LLYCL:Chile LLY:Switzerland LLY:Canada LILY34:Brazil LLY:Bulgaria LLYC:Austria
Address
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Website
https://www.lilly.com
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.